Telormedix Raises CHF 6 M in Series B Financing Round

02.12.2013 09:13

Related tags

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised CHF 6 Million in an extension to its Series B financing.

The money was invested by existing investors Aravis Venture (Zurich, Switzerland) and Proquest Investments (Princeton, USA). The funds will be used to support the on-going Phase II clinical trial of TMX-101 for the treatment of carcinoma in situ (CIS) in the bladder and to finance the planning of a follow on trial for patients with CIS, expected to start in 2014.

TMX-101, Telormedix’ lead compound, a TLR7 agonist, is currently in an open-label Phase II clinical trial involving 12 CIS patients recruited from private urology clinics in the USA, to examine the efficacy of the drug over six doses. The active ingredient in TMX-101 is a known immuno-modulatory molecule with a favourable safety profile and a demonstrated clinical efficacy in oncological and viral diseases.

Johanna Holldack, CEO of Telormedix, commented: “As we near completion of the current Phase II trial in patients with CIS, we are very encouraged by responses observed to date and we remain extremely hopeful that targeting TLR-7 with TMX-101 will prove to be a successful and efficacious treatment option in these patients.”

“The continued support of our committed and supportive investors ensures that we have sufficient funds to complete the current trial and, subject to positive results, move quickly to a pivotal trial” she said.

It is anticipated that the full data from the Phase II trial will be presented at a major urology meeting in the first half of 2014. The enrollment has been completed. Full details of the trial design are available at www.clinicaltrials.gov ID: NCT01731652.

Telormedix has previously raised CHF 28.5M ($31.2M) in venture funding and, with this round, the total is now CHF 34.5M ($37.8M).

About Telormedix
Telormedix, founded in October 2007, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The Company’s lead product, TMX-101, recently entered a Phase I/II clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). In addition, Telormedix is developing two TLR7-targeted molecules, TMX-201 and TMX-202, as a vaccine adjuvant. One of these molecules, TMX-202, has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. The candidate has already successfully completed a number of in vivo studies.

Located in Switzerland, Telormedix is led by a highly experienced management team and backed by an international consortium of venture capitalists Aravis Venture (Zurich, Switzerland) and Proquest Investments (Princeton, USA).

Comments

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Highlights Telormedix

Related News

Related tags

Read more about

Principal

23.09.2016
Editorial

An IPO and CHF 50 million

Partners

Contributors